We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 36

NASDAQ Biotechnology Index surpasses all-time high in 1Q13

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe

Royalty financing gains favor for VC biotech funding

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 29 2013

According to a former venture capitalist (VC), a recent deal involving a royalty in exchange for a cash infusion to develop and commercialize a

Medicinova and Zhejiang Medicine announce joint venture in China

  • Shook Hardy & Bacon LLP
  • -
  • China, USA
  • -
  • March 10 2011

California-based biopharmaceutical company MediciNova Inc. and Zhejiang Medicine Co., a Chinese pharmaceutical manufacturer, have announced a joint venture to develop and commercialize MediciNova’s MN-221 in China

Moneytree report shows increased life sciences investments in Q1 2011

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 19 2011

According to a PricewaterhouseCoopers report on venture capital investments, although fewer deals occurred in the first quarter of 2011 (Q1 2011) as compared to the last quarter of 2010, investment activity increased 5 percent overall

Cincinnati investor closes $4.4 million fund to invest in startups

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 30 2011

Cincinnati-based CincyTech, a venture development company that invests in startup biotech, information technology and advanced manufacturing businesses, has announced the closing of a $4.4 million Fund II targeted for 10 to 12 new startups in southwest Ohio

Fewer small biotech companies go public

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 10 2011

Smaller biotechnology companies maneuvering through drug-development regulations are reportedly focusing their efforts on licensing products in development or selling their businesses to large pharmaceutical companies rather than pursuing an initial public offering (IPO

Quebec establishes new venture capital fund to invest in biotech research

  • Shook Hardy & Bacon LLP
  • -
  • Canada
  • -
  • February 24 2011

Quebec's Charest administration has reportedly launched the third of three new venture capital funds to provide more than $41 million for investment in biotechnology research

Agilent Technologies acquires BIOCIUS Life Sciences

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 10 2011

California-based Agilent Technologies has announced the acquisition of BIOCIUS Life Sciences, a Massachusetts-based company that developed a spectrometry device, enabling "researchers to gain a fuller understanding of a drug's biochemical properties, including potential liabilities in drug interactions

Viropharma to acquire Swedish pharma in deal worth up to $164.6 million

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 3 2011

Pennsylvania-based ViroPharma Inc. has reportedly signed a deal to acquire Swedish company DuoCort Pharma AB to expand its orphan disease commercial product pipeline

Biotech IPO market, booming or bubbling?

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 17 2013

Speakers at a recent Biotechnology Industry Organization (BIO) Investor Forum in San Francisco reportedly claimed that this year's successes for